8 Ways to Create Value in Cancer Care

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Balancing a career as a pediatric oncologist with leadership responsibilities, Maria C. Velez, MD, shares insights into her passion for the field and ASPHO’s impactful work.

Jacob Sands, MD

August 4th 2025

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

Russ Conroy

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

July 31st 2025

NCCN Guidelines Add LEMS Antibody Testing for SCLC

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.

Roman Fabbricatore

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.

Tim Cortese

Leading the Charge in Pediatric Oncology as the New ASPHO President

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.

Related Content

Ariana Pelosci

August 8th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Balancing a career as a pediatric oncologist with leadership responsibilities, Maria C. Velez, MD, shares insights into her passion for the field and ASPHO’s impactful work.

Jacob Sands, MD

August 4th 2025

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Russ Conroy

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

July 31st 2025

NCCN Guidelines Add LEMS Antibody Testing for SCLC

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Roman Fabbricatore

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.

Tim Cortese